Filing Flows › Lenz Therapeutics (LENZ) › Q2 2025
Lenz Therapeutics (LENZ) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 30, 2025
Lenz Therapeutics (LENZ) reported revenue of $5.0M for the second quarter 2025 (Q2 2025). Operating margin was -337.1%, net loss $14.9M (298.2% of revenue).
Lenz Therapeutics, Q2 2025: revenue $5.0M, operating margin -337.1%, net loss $14.9M, operating cash flow −$11.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.0M | — | — |
| Operating profit | −$16.9M | — | — |
| Net earnings | −$14.9M | — | — |
| Operating cash flow | −$11.5M | — | — |
What changed
Revenue was $5.0M in Q2 2025.
Operating costs exceeded revenue by $16.9M, an operating margin of -337.1%. The quarter ended with a net loss of $14.9M.
Operating cash flow was −$11.5M. Non-cash charges added back $19K of depreciation and amortization and $2.8M of share-based compensation. Capital expenditures of $240K exceeded it, leaving free cash flow of −$11.7M.
Questions
What was Lenz Therapeutics' revenue in the second quarter 2025?
Lenz Therapeutics (LENZ) reported revenue of $5.0M for the second quarter 2025 (Q2 2025).
Was Lenz Therapeutics profitable in the second quarter 2025?
Operating loss was $16.9M (-337.1% of revenue) and net loss $14.9M.
Source: Lenz Therapeutics 10-Q on SEC EDGAR.